{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:22:37Z","timestamp":1793924557868,"version":"4.8.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2308,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transthyretin cardiac amyloidosis (ATTR-CA) demonstrates progressive, potentially fatal, and infiltrative cardiomyopathy caused by extracellular deposition of transthyretin-derived insoluble amyloid fibrils in the myocardium. Two distinct types of transthyretin (wild type or variant) become unstable, and misfolding forms aggregate, resulting in amyloid fibrils. ATTR-CA, which has previously been underrecognized and considered to be rare, has been increasingly recognized as a cause of heart failure with preserved ejection fraction among elderly persons. With the advanced technology, the diagnostic tools have been improving for cardiac amyloidosis. Recently, the efficacy of several disease-modifying agents focusing on the amyloidogenic process has been demonstrated. ATTR-CA has been changing from incurable to treatable. Nevertheless, there are still no prognostic improvements due to diagnostic delay or misdiagnosis because of phenotypic heterogeneity and co-morbidities. Thus, it is crucial for clinicians to be aware of this clinical entity for early diagnosis and proper treatment. In this mini-review, we focus on recent advances in diagnosis and treatment of ATTR-CA.<\/jats:p>","DOI":"10.1002\/ehf2.12518","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T17:11:37Z","timestamp":1569431497000},"page":"1128-1139","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Transthyretin Cardiac Amyloidosis: An Update on Diagnosis and Treatment"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-7653","authenticated-orcid":false,"given":"Hiroyuki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Narita-Tomisato Tokushukai Hospital , 1-1-1 Hiyoshidai, Tomisato, Chiba, 286-0201 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Yokochi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Chiba Tokushukai Hospital , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"2026012115084291300_ehf212518-bib-0001","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0002","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026012115084291300_ehf212518-bib-0004","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0005","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","article-title":"Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?","volume":"37","author":"Galat","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0006","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2016.1221815","article-title":"Identification of prognostic markers in transthyretin and AL cardiac amyloidosis","volume":"23","author":"Damy","year":"2016","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0007","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0008","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.amjmed.2005.06.017","article-title":"Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis","volume":"118","author":"Neben-Wittich","year":"2005","journal-title":"Am J Med"},{"key":"2026012115084291300_ehf212518-bib-0009","doi-asserted-by":"crossref","first-page":"838","DOI":"10.7326\/0003-4819-131-11-199912070-00007","article-title":"Systemic amyloidosis presenting with angina pectoris","volume":"131","author":"Al Suwaidi","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026012115084291300_ehf212518-bib-0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"key":"2026012115084291300_ehf212518-bib-0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"2026012115084291300_ehf212518-bib-0013","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0014","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13256-018-1931-5","article-title":"Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report","volume":"12","author":"Yamamoto","year":"2018","journal-title":"J Med Case Reports"},{"key":"2026012115084291300_ehf212518-bib-0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115084291300_ehf212518-bib-0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012115084291300_ehf212518-bib-0018","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0019","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ejhf.1285","article-title":"Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure","volume":"20","author":"Gagliardi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084291300_ehf212518-bib-0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2796.2003.01173.x","article-title":"Hereditary transthyretin amyloidosis from a Scandinavian perspective","volume":"254","author":"Suhr","year":"2003","journal-title":"J Intern Med"},{"key":"2026012115084291300_ehf212518-bib-0021","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0022","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Amyloid Polyneuropathies Network Study G. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Ann Neurol"},{"key":"2026012115084291300_ehf212518-bib-0023","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2026012115084291300_ehf212518-bib-0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173086","article-title":"investigators T. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis\u2014report from the Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"12","author":"Kristen","year":"2017","journal-title":"PLoS ONE"},{"key":"2026012115084291300_ehf212518-bib-0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/13506129.2013.845745","article-title":"Genotype, echocardiography, and survival in familial transthyretin amyloidosis","volume":"20","author":"Arruda-Olson","year":"2013","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0026","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0027","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Conceicao","year":"2019","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0029","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0030","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonzalez-Lopez","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026012115084291300_ehf212518-bib-0032","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0033","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0034","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012115084291300_ehf212518-bib-0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012115084291300_ehf212518-bib-0036","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0037","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0038","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijcard.2016.04.030","article-title":"Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings","volume":"214","author":"Sperry","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0039","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0040","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"2026012115084291300_ehf212518-bib-0041","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012115084291300_ehf212518-bib-0042","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012115084291300_ehf212518-bib-0043","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0044","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115084291300_ehf212518-bib-0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12968-018-0478-3","article-title":"Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis","volume":"20","author":"Ridouani","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012115084291300_ehf212518-bib-0046","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115084291300_ehf212518-bib-0047","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012115084291300_ehf212518-bib-0048","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0049","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0050","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2012.108","article-title":"Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"2026012115084291300_ehf212518-bib-0051","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"2026012115084291300_ehf212518-bib-0052","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0053","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0054","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"2026012115084291300_ehf212518-bib-0056","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0057","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1586\/14779072.2015.1053872","article-title":"Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists","volume":"13","author":"Vaduganathan","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026012115084291300_ehf212518-bib-0058","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1378\/chest.124.3.969","article-title":"Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis","volume":"124","author":"Berk","year":"2003","journal-title":"Chest"},{"key":"2026012115084291300_ehf212518-bib-0059","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026012115084291300_ehf212518-bib-0060","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0061","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0894-7317(99)70091-X","article-title":"Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal echocardiography","volume":"12","author":"Santarone","year":"1999","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012115084291300_ehf212518-bib-0062","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/lt.21996","article-title":"Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience","volume":"16","author":"Barreiros","year":"2010","journal-title":"Liver Transpl"},{"key":"2026012115084291300_ehf212518-bib-0063","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.22184","article-title":"Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant)","volume":"17","author":"Okamoto","year":"2011","journal-title":"Liver Transpl"},{"key":"2026012115084291300_ehf212518-bib-0064","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"key":"2026012115084291300_ehf212518-bib-0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10840-019-00517-y","article-title":"Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?","volume":"55","author":"Milner","year":"2019","journal-title":"J Interv Card Electrophysiol"},{"key":"2026012115084291300_ehf212518-bib-0066","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0735-1097(84)80436-2","article-title":"Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities","volume":"3","author":"Falk","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0067","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"2026012115084291300_ehf212518-bib-0068","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0069","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026012115084291300_ehf212518-bib-0070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"2026012115084291300_ehf212518-bib-0071","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"Holmgren","year":"1991","journal-title":"Clin Genet"},{"key":"2026012115084291300_ehf212518-bib-0072","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00007890-199707150-00014","article-title":"Progression of ventricular wall thickening after liver transplantation for familial amyloidosis","volume":"64","author":"Dubrey","year":"1997","journal-title":"Transplantation"},{"key":"2026012115084291300_ehf212518-bib-0073","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00007890-200203150-00015","article-title":"Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type","volume":"73","author":"Olofsson","year":"2002","journal-title":"Transplantation"},{"key":"2026012115084291300_ehf212518-bib-0074","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","article-title":"Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients","volume":"7","author":"Yazaki","year":"2007","journal-title":"Am J Transplant"},{"key":"2026012115084291300_ehf212518-bib-0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"International Society for Heart Lung Transplantation Infectious Diseases C, International Society for Heart Lung Transplantation Pediatric Transplantation C, International Society for Heart Lung Transplantation Heart F, Transplantation C. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2026012115084291300_ehf212518-bib-0076","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115084291300_ehf212518-bib-0077","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0078","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0079","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115084291300_ehf212518-bib-0080","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012115084291300_ehf212518-bib-0081","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115084291300_ehf212518-bib-0082","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2015.1063485","article-title":"Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)","volume":"22","author":"Cho","year":"2015","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0083","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0084","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1161\/CIRCULATIONAHA.110.955039","article-title":"Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy","volume":"122","author":"Solomon","year":"2010","journal-title":"Circulation"},{"key":"2026012115084291300_ehf212518-bib-0085","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"2026012115084291300_ehf212518-bib-0086","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012115084291300_ehf212518-bib-0087","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0088","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"key":"2026012115084291300_ehf212518-bib-0089","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"2026012115084291300_ehf212518-bib-0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029933","article-title":"Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: \u201cin vivo\u201d evidence from FAP mice models","volume":"7","author":"Ferreira","year":"2012","journal-title":"PLoS ONE"},{"key":"2026012115084291300_ehf212518-bib-0091","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.2147\/DDDT.S96893","article-title":"Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study","volume":"9","author":"aus dem Siepen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026012115084291300_ehf212518-bib-0092","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"2026012115084291300_ehf212518-bib-0093","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","article-title":"Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis","volume":"417","author":"Pepys","year":"2002","journal-title":"Nature"},{"key":"2026012115084291300_ehf212518-bib-0094","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"2026012115084291300_ehf212518-bib-0095","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","article-title":"Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis","volume":"148","author":"Gillmore","year":"2010","journal-title":"Br J Haematol"},{"key":"2026012115084291300_ehf212518-bib-0096","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115084291300_ehf212518-bib-0097","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026012115084291300_ehf212518-bib-0098","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012115084291300_ehf212518-bib-0099","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12518","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/6\/1128\/66136187\/eschf_6_6_1128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/6\/1128\/66136187\/eschf_6_6_1128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:11:05Z","timestamp":1769026265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/6\/1128\/8403497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":99,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,9,25]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12518","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"2019-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}